TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The presence of plaque-type psoriasis in areas of the trunk, buttocks, or extremities that are amenable to biopsy and evaluable disease in at least 2 cm target treatment sites separated by 1 cm~* Age 18-80, both genders, all ethnicities~* No contraindications to phototherapy or biopsy procedures~* No topical steroid, tar, phototherapy, Vitamin D, or retinoid therapy to target lesions for at least 1 week prior to the study~* No systemic psoriasis therapy for at least four weeks prior to the study~* Able to give informed consent under IRB approval procedures~Exclusion Criteria:~* Photosensitivity disorders~* Active untreated diseases or medication usage which may interfere with UVB, wound healing, or immune function~* Hypersensitivity to local anesthetic~* Inability to provide informed consent~* Pregnancy and /or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Imiquimod (Type: OTHER): Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
- Clobetasol (Type: OTHER): Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of the Medtronic Gatekeeper System in the Treatment of SUBJECTS With Gastroesophageal Reflux Disease (GERD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Diagnosis and main criteria for inclusion:~* Subjects diagnosed with GERD with symptomatic improvement on PPIs.~* Subjects who have demonstrated a baseline 24 Hour pH ≥ 4% time with pH ≤ 4.0.~* Subjects with a baseline GERD-HRQL heartburn score of ≤11 on PPI and ≥ 20 off PPI.~Diagnosis and main criteria for exclusion:~* Extensive Barrett's Esophagus (\> 2 cm).~* Esophagitis (LA Classification Grades C or D).~* Previous history of gastroesophageal surgery, anti-reflux procedures, or gastroesophageal or gastric cancer.~* Large hiatal hernia (\> 3 cm).~* Current complaints of clinical dysphagia evidenced by greater than one occurrence per month.~* Esophageal strictures~* Esophageal or gastric varices

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sham (Type: SHAM_COMPARATOR): This arm of the study has the procedure but does not get the Gatekeeper prostheses. The Sham arm has the option to cross-over to the Treatment arm at the 6-month visit.
- Treatment (Type: ACTIVE_COMPARATOR): The treatment arm has the Gatekeeper devices implanted.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Either of the following: Mild Diabetes Mellitus or Stress Hyperglycemia~* AND:~* Cardiac Surgery~* Insulin Requirement between 8-30 units subcutaneous on post-op day 3 or later off pressors, off enteral feeding, extubated OR glucose \>150 mg/dL at least twice in a 24 hour period (\>4 hours apart) and otherwise not requiring basal insulin~Exclusion Criteria:~* use of pressors, mechanical ventilation, or enteral or parenteral feeding within previous 12 hours~* glucocorticoids in doses exceeding the equivalent of Prednisone 10 mg/day within the previous 48 hours~* left ventricular assist device~* percutaneous or laparoscopic surgery~* end stage renal disease~* end stage liver disease~* history of pancreatitis~* type 1 diabetes~* pregnancy~* unable to give consent in english~* no phone~* prisoners~* less than 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
- Placebo (Type: PLACEBO_COMPARATOR): Patients will receive placebo prior to discharge and 6 weeks after discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The ACHIEVA Study of Enhanced Pharmacist Care on Antidepressant Use and Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patient presents to a pharmacy with a prescription for an antidepressant from a family physician~* patient with DSM-IV major or minor depression~* patient has not taken an antidepressant in the preceding six months~* patient is 18 years of age or older~* patient is fluent in English~* patient taking newly-prescribed antidepressant for no more than 1 week~Exclusion Criteria:~* patient with plans of leaving the vicinity within 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with a history of chronic anemia defined as a documented Hb value of \<= 11.0 g/dL~* No active cancer~* At least 65 years of age with life expectancy of \> 6 months~* Community dwelling patients~* Patients with a Short Physical Performance (SPPB) Summary Score of 4-10 at screening and baseline~* Patients with an Mini Mental State Examination (MMSE) score \>= 24~Exclusion Criteria:~* Positive stool guaiac test~* Diagnosis of multiple myeloma and/or MGUS~* History of venous thromboembolytic disease~* Previous treatment with Epoetin alfa, Darbepoetin or any form of erythropoietin recently~* Uncontrolled or severe cardiovascular disease

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older~2. Male or non-pregnant female patients~3. Admitted to the hospital with a primary diagnosis of acute decompensated heart failure (ADHF)~4. On regularly scheduled oral loop diuretics prior to admission~5. Fluid overload manifested by at least two of the following:~   1. Pitting edema (2+) of the lower extremities~  2. Jugular venous distention \> 8 cm~  3. Pulmonary edema or pleural effusion on chest x-ray~  4. Paroxysmal nocturnal dyspnea or ≥ two- pillow orthopnea~  5. Respiration rate ≥ 20 per minute.~6. Have received ≤ 2 IV loop diuretics doses before randomization~7. Must be able to be enrolled into the trial ≤ 24 hours of their admission to the hospital.~8. Provide written informed consent form as required by the local IRB (Institutional Review Board)~Exclusion Criteria:~1. Acute coronary syndromes~2. Renal insufficiency with a sCr ≥ 3.0 mg/dl or planned renal replacement therapies~3. Systolic blood pressure \< 90 mmHg at time of enrollment~4. Pulmonary Arterial Hypertension not secondary to left heart disease~5. Contraindications to systemic anticoagulation~6. Hematocrit \> 45%~7. Inability to obtain venous access~8. Hemodynamic instability severe enough to require IV positive inotropic agents, IV vasodilators or both~9. Use of iodinated radiocontrast material within the previous 72 hours or planned study requiring IV contrast during the current hospitalization~10. Severe concomitant disease expected to prolong hospitalization~11. Severe concomitant disease expected to cause death in ≤ 90 days~12. Sepsis or ongoing systemic infection~13. Severe uncorrected valvular stenosis~14. Active myocarditis~15. Hypertrophic obstructive cardiomyopathy~16. Constrictive pericarditis or restrictive cardiomyopathy~17. Liver cirrhosis~18. Previous solid organ transplant~19. Requirement for mechanical ventilatory support~20. Presence of a mechanical circulatory support device~21. Unwillingness or inability to complete follow up~22. Active drug or ETOH substance abuse~23. Participating in another interventional clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aquapheresis (AQ) - isolated veno-venous ultrafiltration (Type: EXPERIMENTAL): Excess fluid from the patient is removed by isolated veno-venous ultrafiltration treatment using the Aquadex Flex Flow System
- IV Loop Diuretics (LD) (Type: ACTIVE_COMPARATOR): Excess fluid from the patient is removed by IV (Intravenous) loop diuretic treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants weighing \<1250 grams at birth with respiratory distress syndrome who have respiratory infection with Ureaplasma sp organisms.~Exclusion Criteria:~* Severe respiratory distress syndrome with survival unlikely \>7 days, Congenital malformations

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 3 Days
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Early treatment with azithromycin
- 2 (Type: NO_INTERVENTION): Expectant (usual) management

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: General Anesthesia With Xenon in Inspiratory Concentrations of 50% and 70% and Total I.V. Anaesthesia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient ≥ 50 years old~* ASA (American Society of Anaesthesiologists) Physical Status III~* Patient with increased risk of perioperative cardiac complications (Revised Cardiac Risk Index\>=2)~* Surgical operation: laparotomy or orthopaedic surgery or laparoscopy~* Planned duration of general anaesthesia in the range of 2-6 hours~* Patient willing and able to complete the requirements of this study including the signature of the written informed consent~Exclusion Criteria:~* Patient with severe impairment of cardiac function (Left Ventricular Ejection Fraction \< 35%)~* Patient with drug-eluting stent placed within 12 months prior to selection~* Woman of child-bearing potential not implementing adequate contraceptive methods~* Pregnant or lactating woman~* Surgical procedure in emergency~* Chronic opioids pain therapy~* Serious illness or medical conditions which are possible contra indication for elective general anaesthesia or administration of intra operative treatments, or which are interfering with the monitoring devices, such as:~  * Myocardial infarction within 6 months prior to selection~ * Any significant history of allergy/hypersensitivity to any drugs used during the study, to silicone or to latex~ * Severely impaired hearing~ * Known severe neurological disorders~ * Any medical condition which does not justify the trial participation in the investigator's judgement~ * General anaesthesia within 7 days prior to selection~ * Laparotomy within 3 months prior to selection, only for patients undergoing laparotomy~* History of drug abuse or psychiatric disorders which would impair the understanding of the necessary information or render medically or legally not able to give written informed consent~* Concurrent treatment with any other experimental drugs~* Participation in any other clinical trial within 4 weeks prior to selection

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Xenon 50% (45%-55%) in Oxygen (45%-55%),
- Group B (Type: EXPERIMENTAL): Xenon 70% (65%-75%) in Oxygen (25%-35%)
- Group C (Type: ACTIVE_COMPARATOR): Medical Air in Oxygen (45%-55%)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intra-Operative Dural Brachytherapy With Yttrium-90 Plaque Applicators

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathological diagnosis of malignant tumor involving spine with extraosseous extension or arising in paraspinal soft tissues with tumor involving or abutting the dura. Patients with a limited metastatic disease and tumor involving the spine or paraspinal soft tissues and who are judged to benefit from surgery will also be eligible.~* Lesion may be primary or recurrent after prior surgery~* No clinical, radiographic or other evidence of distant metastatic tumor~* Fit for receiving the planned radiation dose to the affected site. No known genetic disease or medical condition associated with an abnormal radiation sensitivity.~* 18 years of age or older~* KPS of 70 or greater (excluding consideration of poor function due to the local growth or systemic metabolic effects of the tumor~Exclusion Criteria:~* Disease/conditions characterized by high radiation sensitivity~* Pregnancy~* Evidence of cord/cauda malfunction for causes other than effect os local tumor growth or due to metabolic effects of tumor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dural brachytherapy plaque (Type: EXPERIMENTAL): Patients undergoing spine tumor resection will undergo dural plaque brachytherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Micafungin Lock Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children, 6 months-18 yrs, with a central line fungal infection, presumed Candida, admitted at Children's Medical Center.~* Signed informed consent by parents and assent by minor if applicable.~* Subjects with likely survival beyond 1 week.~Exclusion Criteria:~* Pocket, tunnel or exit-site infection~* Known allergic reactions to the Micafungin or echinocandins.~* Severe systemic symptoms (disseminated candidemia, fungal balls, endocarditis)~* Mixed infections~* Inability to lock the catheter lumen for minimum 8h because of other medications administration~* Subjects requiring ECMO or CVVH.~* Patients with HIV, congenital immunodeficiencies.~* Positive pregnancy test or breastfeeding.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): ALT with placebo with systemic Micafungin therapy
- 2 (Type: EXPERIMENTAL): ALT with Micafungin and heparin with systemic Micafungin therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Remote Ischemic Preconditioning Living Donor Renal Transplant Protocol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> OR = 19 years of age receiving a living donor renal transplant (treatment control group) and their donors (control group donors)~Exclusion Criteria:~* \< 19 years of age~* No safe extremity to place tourniquet~* Patients with previous muscle, vascular, or nerve injury to an extremity,~* Patients with only one available extremity that has an arteriovenous fistula~* Patients who are hemodialysis dependent who have not received hemodialysis in the past 4 days~* Paraplegic/quadriplegic patients~* Active pathologic cutaneous lesions on extremities~* Patients with a history of tourniquet pain or complex regional pain syndrome (CRPS)~* Pregnant patients

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): The treatment will receive 200 mmHg of pressure from a Zimmer automatic tourniquet system (ATS) for three 5 minute intervals.
- Control Group (Type: EXPERIMENTAL): Our control group will receive 20 mmHg of pressure from a Zimmer automatic tourniquet system (ATS) for three 5 minute intervals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis of CIDP based upon clinical/electrophysiological criteria~* On treatment for CIDP including IVIG and/ or steroids/plasma exchange~Exclusion criteria:~* Inherited polyneuropathy, such as Charcot Tooth Marie disease~* Abnormal baseline EKG, heart disease, epilepsy, pregnancy, multiple sclerosis and diabetes mellitus

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Non-invasive vagus nerve stimulation (nVNS) (Type: EXPERIMENTAL): Participants will use the electrical neuromuscular stimulator device, VitalStim 400, which has been used in previous clinical studies for modulation of pain and has received FDA approval. Participants will also continue to take their standard of care medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Nicardipine to Treat Cerebral Vasospasm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 years of age and older~* Subarachnoid hemorrhage documented on head CT~* Fisher Grade 3 or 4~* Hunt Hess Grade 1-5~* Cerebral aneurysm as definitive source of subarachnoid hemorrhage~* Cerebral aneurysm must be treated via open or endovascular techniques~* Presence of external ventricular drain~* Written informed consent obtained from subject or subject's legally authorized representative~Exclusion Criteria:~* Absence or inability to have an external ventricular drain (coagulopathy)~* Non-aneurysmal subarachnoid hemorrhage (perimesencephalic)~* Untreated cerebral aneurysm~* Inability to be randomized prior to post-hemorrhage day 4~* Elevated intra-cranial pressures that would preclude external ventricular drain clamping for 30-60 minutes~* Inability to administer study medication (severe intra-ventricular hemorrhage, occluded external ventricular drain)~* Inability to obtain angiography (coagulopathy, renal failure)~* Pregnant~* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nicardipine hydrochloride (Type: EXPERIMENTAL): Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
- Preservative-free normal saline (Type: PLACEBO_COMPARATOR): Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy